Since listing “Race” the story and journey of Bisantrene has...

Since listing “Race” the story and journey of Bisantrene has grown many tentacles through internal company research and development, and interested shareholder investigation and chats. The list of scenarios and potential for trial use of “Bis” in conjunction or collaboration with an expanding number of other treatments and drugs/compounds etc seems almost unwieldy.

The potential revenue streams and size of Race Market Capitalization is compounding commensurately as well.

Is executive and the legal team in a “Race” (pardon the pun) to make waterproof our IP?

Currently I feel posters think our IP is safe, but I wonder with this seemingly limitless potential Race continues to uncover is the IP nailed to the floor, is it tighter than the proverbial “fishes bum”?

Is the question of IP assurance the missing link for institutional and well healed professional investors?

As shareholders do we need an Announcement concreting our IP protection?